Change in macular thickness in a case of refractory diabetic macular edema with dexamethasone intravitreal implant in comparison to intravitreal bevacizumab: a case report.

Abstract

We report on the significant improvement of central macular thickness in a case of clinically significant macular edema after dexamethasone 0.7 mg sustained-release intravitreal implant (Ozurdex®; Allergan, Inc, Irvine, CA, USA). Patient presented to us with persistent clinically significant macular edema (CSME) in both eyes. Right eye received dexamethasone implant and left eye received two intravitreal bevacizumab injections 1.25 mg/0.05 mL (Avastin®; Genentech Inc., South San Francisco, CA, USA) with an interval of four weeks. After six weeks of follow-up, dexamethasone implant in the right eye showed normal macular thickness whereas persistent macular edema (ME) was found even after second intravitreal bevacizumab injection in the left eye.

• Authors: Ashish Sharma, Rangasamy J Madhusudhan, Vidhya Nadahalli, Shreekant A Damgude, Selva K Sundaramoorthy
• Journal: Indian journal of ophthalmology (Indian J Ophthalmol) 2012 May-Jun Vol. 60 Issue 3 Pg. 234-5 ISSN: 1998-3689 [Electronic] India
• PMID: 22569393 (Publication Type: Case Reports, Journal Article)

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal, Humanized
• Drug Implants
• Glucocorticoids
• Vascular Endothelial Growth Factor A
• Bevacizumab
• Dexamethasone

Topics

• Adult
• Angiogenesis Inhibitors (administration & dosage)
• Antibodies, Monoclonal, Humanized (administration & dosage)
• Bevacizumab
• Dexamethasone (administration & dosage)
• Diabetic Retinopathy (complications, drug therapy, pathology)
• Disease Progression
• Drug Implants
• Follow-Up Studies
• Glucocorticoids (administration & dosage)
• Humans
• Intravitreal Injections
• Macula Lutea (drug effects, pathology)
• Macular Edema (drug therapy, etiology, pathology)
• Male
• Tomography, Optical Coherence
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)
• Visual Acuity